Compare Cassava Sciences Inc (FLNA) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NetEase Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while NetEase Inc trades at $124.49 (market cap $83.89B). The key difference: NetEase Inc is far larger — about 1756.9× Cassava Sciences Inc's market cap, and NetEase Inc pays a 2.26% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NTES | |
|---|---|---|
Market Cap | $47.75M | $83.89B |
Sector | Health | Media |
52-Week High | $4.64 | $159.34 |
52-Week Low | $0.87 | $109.26 |
Enterprise Value | -$34.93M | $60.18B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
NTES trades at $132.22, up 1.43% today, with a bullish technical signal from moving averages and support near $131. The company reported Q1 2026 EPS of $2.53, beating estimates, and maintains strong profitability with a 29.84% net income margin. Recent news highlights upcoming Q2 2026 earnings on August 20, 2026, amid positive sentiment for Chinese tech stocks.
Outlook is positive with 82% analyst buy ratings and a 34.7% upside potential, though risks include earnings volatility and regulatory pressures. Revenue growth to $114.4B in 2026 and robust cash flow support valuation, but investors should monitor execution amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
